BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28050694)

  • 1. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
    Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
    J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
    Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
    Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases.
    Leitner J; Pelster S; Schöpf V; Berghoff AS; Woitek R; Asenbaum U; Nenning KH; Widhalm G; Kiesel B; Gatterbauer B; Dieckmann K; Birner P; Prayer D; Preusser M; Furtner J
    PLoS One; 2018; 13(11):e0207849. PubMed ID: 30496307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis.
    Kim YI; Shin JY; Yang SH; Kim HH; Shim BY; Ahn S
    Curr Oncol; 2022 Sep; 29(9):6463-6471. PubMed ID: 36135077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC.
    Woody NM; Greer MD; Reddy CA; Videtic GMM; Chao ST; Murphy ES; Suh JH; Angelov L; Barnett GH; Vogelbaum MA; Stephans KL
    Clin Lung Cancer; 2018 Jan; 19(1):e141-e147. PubMed ID: 28739316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
    Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
    Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
    Yesil Cinkir H; Colakoglu Er H
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma.
    Lee B; Bae YJ; Jeong WJ; Kim H; Choi BS; Kim JH
    Sci Rep; 2021 Oct; 11(1):19717. PubMed ID: 34611230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of temporal muscle thickness, a novel radiographic marker of sarcopenia, in patients with brain tumor: A systematic review and meta-analysis.
    Yang YW; Ming Yang ; Zhou YW; Xia X; Jia SL; Zhao YL; Zhou LX; Cao Y; Ge ML
    Nutrition; 2023 Aug; 112():112077. PubMed ID: 37236042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
    Aoyama H; Tago M; Shirato H;
    JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
    Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
    Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors for non-small cell lung cancer patients with central nervous system metastasis with positive driver genes].
    Li R; Zhang SR; Liu XF; Zhang JW; Zhao JY; Bai P; Zhang XC
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1202-1209. PubMed ID: 37087403
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1-10 brain metastases treated with stereotactic radiosurgery.
    Nagtegaal SHJ; Claes A; Suijkerbuijk KPM; Schramel FMNH; Snijders TJ; Verhoeff JJC
    Radiother Oncol; 2019 Sep; 138():173-179. PubMed ID: 31302392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
    Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
    Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
    An G; Ahn S; Park JS; Jeun SS; Hong YK
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases.
    Subbiah IM; Lei X; Weinberg JS; Sulman EP; Chavez-MacGregor M; Tripathy D; Gupta R; Varma A; Chouhan J; Guevarra RP; Valero V; Gilbert MR; Gonzalez-Angulo AM
    J Clin Oncol; 2015 Jul; 33(20):2239-45. PubMed ID: 25987700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor.
    Zhuang Q; Wong RX; Lian WX; Li YQ; Wong FY
    Ann Palliat Med; 2019 Sep; 8(4):390-400. PubMed ID: 30943738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y
    Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.